June 1, 2017
Payments linked to higher odds of doctors prescribing certain cancer drugs
In preliminary findings presented at the American Society of Clinical Oncology Annual Meeting 2017, researchers show that when physicians had to choose between multiple, on-patent drugs for metastatic kidney cancer and chronic myeloid leukemia, they were more likely to prescribe drugs from companies they had received general payments from.